Aquatic Capital Management LLC Purchases Shares of 15,694 Denali Therapeutics Inc. (NASDAQ:DNLI)

Aquatic Capital Management LLC acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 15,694 shares of the company's stock, valued at approximately $320,000.

A number of other institutional investors also recently made changes to their positions in the company. Sterling Capital Management LLC boosted its stake in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after acquiring an additional 885 shares during the period. KBC Group NV grew its stake in shares of Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares in the last quarter. AlphaQuest LLC increased its position in Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after acquiring an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. raised its stake in Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after purchasing an additional 2,436 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Stock Performance

NASDAQ DNLI remained flat at $14.43 on Friday. 566,133 shares of the company's stock traded hands, compared to its average volume of 1,087,297. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -5.23 and a beta of 1.49. The stock's fifty day simple moving average is $14.30 and its 200-day simple moving average is $20.16. Denali Therapeutics Inc. has a 1 year low of $10.57 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the previous year, the business earned ($0.68) earnings per share. As a group, research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Robert W. Baird decreased their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research report on Thursday. Cantor Fitzgerald upgraded Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. Oppenheimer cut their target price on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, B. Riley reiterated a "buy" rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $33.79.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.